Ovid Therapeutics To Participate In Upcoming Investor Conferences
- Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET H.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET
Webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcasts will be available on the Company's website following the live presentation for approximately 30 days.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The Company discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant FOS and DEEs, including TSC and IS; and OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit
Contact
Investor Relations & Media
...
202.361.0445
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment